- Home
- KLRS vs EDRY Comparison
KLRS vs EDRY Comparison
Compare KLRS & EDRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | EDRY |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 36.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KLRS | EDRY |
|---|---|---|
| Price | $8.50 | $13.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.50 | N/A |
| AVG Volume (30 Days) | ★ 166.4K | 3.1K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,384,447.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.14 | $7.60 |
| 52 Week High | $12.90 | $16.14 |
Technical Indicators
Market Signals| Indicator | KLRS | EDRY |
|---|---|---|
| Relative Strength Index (RSI) | 71.30 | 50.84 |
| Support Level | $5.58 | $13.10 |
| Resistance Level | $6.27 | $13.75 |
| Average True Range (ATR) | 0.74 | 0.32 |
| MACD | 0.26 | -0.02 |
| Stochastic Oscillator | 87.65 | 52.33 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.